New drug approvals in acute myeloid leukemia: what's the best end point?

Leukemia. 2016 Mar;30(3):521-5. doi: 10.1038/leu.2015.262. Epub 2015 Dec 18.

Authors

E Estey¹, M Othus², S J Lee³, F R Appelbaum³, R P Gale⁴

Affiliations

¹ Clinical Research Division and Division of Hematology, Fred Hutchinson Cancer Research Center, University of Washington, Seattle, WA, USA.
² Public Health Sciences Division's Biostatistics and Biomathematics Group, Fred Hutchinson Cancer Research Center, University of Washington, Seattle, WA, USA.
³ Clinical Research Division and Division of Medical Oncology, University of Washington, Seattle, WA, USA.
⁴ Division of Experimental Medicine, Department of Medicine, Haematology Research Centre, Imperial College London, London, UK.

No abstract available

Publication types

Editorial
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't

MeSH terms

Biomarkers, Pharmacological / analysis*
Bone Marrow Transplantation*
Drug Approval / legislation & jurisprudence*
Drugs, Investigational / therapeutic use*
Fusion Proteins, bcr-abl / genetics
Fusion Proteins, bcr-abl / metabolism
Gene Expression
Humans
Leukemia, Myeloid, Acute / diagnosis
Leukemia, Myeloid, Acute / mortality
Leukemia, Myeloid, Acute / pathology
Leukemia, Myeloid, Acute / therapy*
Neoplasm, Residual
Prognosis
Quality of Life
Remission Induction
Survival Analysis
United States

Substances

BCR-ABL1 fusion protein, human
Biomarkers, Pharmacological
Drugs, Investigational
Fusion Proteins, bcr-abl

Grants and funding